Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 15.46%.

  • Arrowhead Pharmaceuticals' EBIT Margin rose 64719400.0% to 15.46% in Q4 2025 from the same period last year, while for Dec 2025 it was 27.55%, marking a year-over-year increase of 250654300.0%. This contributed to the annual value of 11.86% for FY2025, which is 169389200.0% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its EBIT Margin stood at 15.46% for Q4 2025, which was up 64719400.0% from 17.2% recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' EBIT Margin's 5-year high stood at 70.24% during Q1 2025, with a 5-year trough of 6456.48% in Q4 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' EBIT Margin had a median value of 169.48% in 2021 and averaged 774.72%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -37778900bps in 2023, then skyrocketed by 64719400bps in 2025.
  • Arrowhead Pharmaceuticals' EBIT Margin (Quarter) stood at 230.77% in 2021, then skyrocketed by 71bps to 67.36% in 2022, then tumbled by -5608bps to 3845.25% in 2023, then plummeted by -68bps to 6456.48% in 2024, then surged by 100bps to 15.46% in 2025.
  • Its EBIT Margin was 15.46% in Q4 2025, compared to 17.2% in Q3 2025 and 596.21% in Q2 2025.